FDA launches pilot to accelerate phase 1

The U.S. Food and Drug Administration has launched a pilot program designed to speed up the sluggish pace of early-stage clinical trials. The initiative will pair drug sponsors with selected qualified research institutions to submit investigational new drug applications on a faster, rolling basis.

Acting FDA Commissioner Kyle Diamantas announced the program. He stated that the pilot aims to test if such partnerships can accelerate processes after the agency allows a trial to proceed. The FDA hopes this will help put U.S. Phase 1 trial timelines on par with those in countries like China and Australia.

Program Structure and Selection

The finalized pilot will match sponsors with qualified research institutions, which can include contract research organizations, academic medical centers, and regulatory advisors. FDA staff will review applications and select approximately eight to ten sponsor-institution pairs for the program. Submissions are being accepted until October 30.

When choosing participants, the agency will prioritize sponsors with novel investigational products for diseases with severe unmet need. These sponsors must also have already generated sufficient preclinical data for the FDA to assess their IND prospects. For the research institutions, the FDA will select proven leaders in several core scientific and regulatory disciplines.

The required core disciplines for qualified research institutions are:

Goals and Broader Context

This pilot is part of a broader FDA initiative called Operation Trial Blazer, which was announced in June. The ultimate goal, according to Diamantas, is to reduce phase 1 trial timelines by six months to a year. The program will also include other efforts across the Department of Health and Human Services.

Michael Davis, M.D., Ph.D., the new head of the FDA’s Center for Drug Evaluation and Research, commented on the program's development. "The FDA greatly appreciates the public feedback we received on the proposed pilot, and we have incorporated that feedback into the final pilot design," Davis said in the agency's release. He added that the FDA is committed to ensuring the United States remains the global standard for pharmaceutical innovation and regulatory rigor.

International Pressure and Concerns

The pace of phase 1 trials in the United States has become an area of increasing regulatory concern. Other countries, notably Australia and China, have much speedier processes for moving promising new drugs into human testing. However, China's pathway of investigator-initiated trials has recently come under scrutiny. This follows the revelation of numerous patient deaths that were not previously disclosed.